Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms:a pragmatic study

Archive ouverte

Orvain, Corentin | Luque Paz, Damien | Dobo, Irène | Cottin, Laurane | Le Calvez, Geneviève | Chauveau, Aurélie | Mercier, Mélanie | Farhi, J. | Boyer, Françoise | Ianotto, Jean-Christophe | Guibourg, Briac | Rousselet, Marie- Christine | Zandecki, Marc | Ifrah, Norbert | Hunault-Berger, Mathilde | Ugo, Valérie | Genevieve, Franck

Edité par CCSD ; Springer Verlag -

International audience. A high number of circulating CD34+ cells has been advocated to distinguish primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms. We reevaluated the diagnostic interest of measuring circulating CD34+ cells in 26 healthy volunteers and 256 consecutive patients at diagnosis for whom a myeloproliferative neoplasm was suspected. The ROC curve analysis showed that a number of CD34+ <10/μl excludes the diagnosis of primary myelofibrosis with a sensitivity of 97%and a specificity of 90%(area under the curve: 0.93 [0.89–0.98]; p < 0.001). Patients with PMF harboring a CALR mutation had more circulating CD34+ cells than patients with either a JAK 2 or MPL mutation (p = 0.02 and p < 0.01, respectively). These results suggest that this fast, simple, non-invasive, and standardized test is of particular interest to exclude the diagnosis of primarymyelofibrosis.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion